Moderna: ESMO Answered The Science, Q3 Has To Answer The Money (NASDAQ:MRNA)
· seekingalpha.com
Why Moderna remains a Sell: ESMO data, valuation risks, pricing hurdles, and key upcoming catalysts.
In my last article on Moderna ( MRNA ), I rated the stock a Sell and said that I would be looking at three things at ESMO , whether the hazard ratio comes in cl...